Pituitary Adenomas: Insights into the Recent Trends

Ahmed M. Kabel^1,

¹Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Cite this paper:
Ahmed M. Kabel. Pituitary Adenomas: Insights into the Recent Trends. Journal of Cancer Research and Treatment. 2020; 8(2):21-24. doi: 10.12691/jcrt-8-2-3

Abstract

Pituitary adenoma is a type of pituitary neoplasms that is typically a benign, slow-growing tumor that arises from cells in the pituitary gland. Pituitary adenomas are classified according to their secretory products into functioning (Endocrine-active) tumors that represent almost 70% of pituitary tumors, and non-functioning adenomas (Endocrine-inactive). Because of physiologic effects of excess hormones, the functioning tumors present earlier than non-functioning adenomas. Patients with pituitary adenomas usually present with symptoms related to hormonal disturbances. However, pressure symptoms, such as headache, visual field defects, cranial nerve palsies and hypopituitarism may occur due to the mass effect of large tumors. Treatment of pituitary adenomas include transsphenoidal surgery and adjunctive therapy including supervoltage radiation and pharmacologic agents. This review throws light on pituitary adenoma regarding its prevalence, predisposing factors, types, clinical presentation, diagnosis and possible lines of management in view of the recent trends.

Keywords:
pituitary adenomas hypopituitarism diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health 2014; 2(4): 48-51.
[2]	Sharif-Alhoseini M, Rahimi-Movaghar V. Pituitary adenomas: a review. J Inj Violence Res 2012; 4:56.
[3]	Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA 2017; 317(5): 516-24.
[4]	Varlamov EV, McCartney S, Fleseriu M. Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies. Eur Endocrinol 2019;15(1): 30-40.
[5]	Aljabri KS, Bokhari SA, Assiri FY, Alshareef MA, Khan PM. The epidemiology of pituitary adenomas in a community-based hospital: a retrospective single center study in Saudi Arabia. Ann Saudi Med 2016; 36(5): 341-5.
[6]	Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014; 117(3): 379-94.
[7]	Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 2018; 21(2): 111-8.
[8]	Syro LV, Rotondo F, Ramirez A, et al. Progress in the Diagnosis and Classification of Pituitary Adenomas. Front Endocrinol (Lausanne) 2015; 6: 97.
[9]	Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab 2019; 104(7): 2473-89.
[10]	Inoshita N, Nishioka H. The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol 2018; 35(2): 51-6.
[11]	Das B, Batool S, Khoja A, Islam N. Presentation, Management, and Outcomes of Nonfunctioning Pituitary Adenomas: An Experience from a Developing Country. Cureus 2019; 11(9): e5759.
[12]	Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci 2015; 22(10): 1562-7.
[13]	Uraki S, Ariyasu H, Doi A, et al. Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy. Endocrinol Diabetes Metab Case Rep 2017; 2017: 17-0027.
[14]	Penner F, Prencipe N, Pennacchietti V, et al. Super Giant Growth Hormone-Secreting Pituitary Adenoma in Young Woman: From Ventricles to Nose. World Neurosurg 2019; 122: 544-8.
[15]	Tatsi C, Stratakis CA. The Genetics of Pituitary Adenomas. J Clin Med 2019; 9(1): 30.
[16]	Vasilev V, Daly A, Naves L, Zacharieva S, Beckers A. Clinical and genetic aspects of familial isolated pituitary adenomas. Clinics (Sao Paulo) 2012; 67 (1): 37-41.
[17]	Kabel AM, Omar MS, Balaha MF, Borg HM. Effect of metformin and adriamycin on transplantable tumor model. Tissue Cell 2015; 47(5): 498-505.
[18]	Anvari K, Kalantari MR, Samini F, Shahidsales S, Seilanian-Toussi M, Ghorbanpour Z. Assessment of clinicopathologic features in patients with pituitary adenomas in Northeast of Iran: A 13-year retrospective study. Iran J Neurol 2015; 14(4): 185-9.
[19]	Andela CD, Lobatto DJ, Pereira AM, van Furth WR, Biermasz NR. How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. Pituitary 2018; 21(2): 208-16.
[20]	Araujo-Castro M, Berrocal VR, Pascual-Corrales E. Pituitary tumors: epidemiology and clinical presentation spectrum. Hormones 2020; 19: 145-55.
[21]	Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. Am Fam Physician 2013; 88(5): 319-27.
[22]	Zhan R, Zhao Y, Wiebe TM, Li X. Acute Hemorrhagic Apoplectic Pituitary Adenoma: Endoscopic Management, Surgical Outcomes, and Complications. J Craniofac Surg 2015; 26(6): e510-e515.
[23]	Schreckinger M, Szerlip N, Mittal S. Diabetes insipidus following resection of pituitary tumors. Clin Neurol Neurosurg 2013; 115(2): 121-6.
[24]	Kim SY. Diagnosis and Treatment of Hypopituitarism. Endocrinol Metab (Seoul) 2015; 30(4): 443-55.
[25]	Langlois F, McCartney S, Fleseriu M. Recent Progress in the Medical Therapy of Pituitary Tumors. Endocrinol Metab (Seoul) 2017; 32(2): 162-70.
[26]	Tirosh A, Shimon I. Current approach to treatments for prolactinomas. Minerva Endocrinol 2016; 41(3): 316-23.
[27]	Mori R, Inoshita N, Takahashi-Fujigasaki J, et al. Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution. ISRN Endocrinol 2013; 2013: 723432.
[28]	Waligórska-Stachura J, Gut P, Sawicka-Gutaj N, et al. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report. J Neurosurg 2016; 125(2): 346-9.
[29]	Mathioudakis N, Pendleton C, Quinones-Hinojosa A, Wand GS, Salvatori R. ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity. Pituitary 2012; 15(4): 526-32.
[30]	Langlois F, Chu J, Fleseriu M. Pituitary-Directed Therapies for Cushing's Disease. Front Endocrinol (Lausanne) 2018; 9: 164.
[31]	Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves' disease: a case report. J Med Case Rep 2013; 7: 27.
[32]	Esposito D, Olsson DS, Ragnarsson O, Buchfelder M, Skoglund T, Johannsson G. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary 2019; 22(4): 422-34.
[33]	Dai C, Liu X, Ma W, Wang R. The Treatment of Refractory Pituitary Adenomas. Front Endocrinol (Lausanne) 2019; 10: 334.
[34]	Theodros D, Patel M, Ruzevick J, Lim M, Bettegowda C. Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol 2015; 4(6): 411-29.
[35]	Hirohata T, Ishii Y, Matsuno A. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Neurol Med Chir (Tokyo) 2014; 54(12): 966-73.